Immunohistochemical Analysis of Programmed Death-Ligand 1 Expression in Equine Sarcoids.
Authors: Benvegnen Jennifer, De Breuyn Bettina, Gerber Vinzenz, Rottenberg Sven, Koch Christoph
Journal: Journal of equine veterinary science
Summary
# Editorial Summary: PD-L1 Expression in Equine Sarcoids Sarcoids represent the most common equine skin tumour, yet their immunological mechanisms remain incompletely understood. Benvegnen and colleagues investigated whether these tumours evade the immune system through programmed death-ligand 1 (PD-L1) expression—a checkpoint protein that cancers exploit to suppress T cell-mediated destruction—using immunohistochemical analysis of formalin-fixed tissue samples with antibodies originally developed for human PD-L1 screening. Contrary to expectations based on mechanisms observed in human and other animal cancers, the researchers found minimal or absent PD-L1 expression across their sarcoid samples, suggesting this particular immune evasion pathway is not a significant feature of equine sarcoid biology. These findings have meaningful implications for treatment strategy; they indicate that immunotherapies targeting the PD-1/PD-L1 axis—an increasingly promising approach in human oncology—are unlikely to represent an effective therapeutic avenue for managing equine sarcoids. Whilst this negative result may seem discouraging, it redirects clinical and research attention towards alternative immune mechanisms or non-immunological factors that better explain sarcoid persistence and treatment resistance, ultimately supporting more targeted and evidence-based therapeutic development.
Read the full abstract on PubMed
Practical Takeaways
- •PD-L1 checkpoint inhibitor immunotherapy is unlikely to be an effective treatment approach for equine sarcoids based on current evidence of minimal PD-L1 expression
- •Veterinarians should continue to rely on established sarcoid treatment modalities rather than anticipating checkpoint inhibitor therapies
- •Further investigation into alternative immune evasion mechanisms in equine sarcoids may be warranted to identify more promising immunotherapeutic targets
Key Findings
- •Human anti-PD-L1 antibodies showed cross-reactivity with equine PD-L1 in immunohistochemical testing of formalin-fixed, paraffin-embedded sarcoid tissues
- •PD-L1-mediated immune evasion does not appear to play an important role in equine sarcoid disease pathogenesis
- •Results do not support a rationale for anti-PD-1/PD-L1-based immunotherapy as a treatment strategy for equine sarcoids